title: [Prostate cancer].
abstract: Up to stage B1 or prostate cancer with N0-1 positive lymph node may be curable by monotherapy of either radical prostatectomy or irradiation. Localized but more advanced stages (B2 and C), however, are difficult to cure. To further improve the prognosis in these stages, a new treatment modality is proposed; pelvic lymphadenectomy, followed by irradiation with neoadjuvant and adjuvant endocrine therapy. An average 2-year followup is favorable. Further studies is awaited to make conclusion.
authors.affiliation: Department of Urology, School of Medicine, Chiba University, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Shimazaki
authors.forename: S
authors.initials: S
authors.lastname: Isaka
authors.forename: K
authors.initials: K
authors.lastname: Akakura
authors.forename: S
authors.initials: S
authors.lastname: Akimoto
authors.forename: S
authors.initials: S
authors.lastname: Morita
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000008:administration & dosage*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D011879:Radiotherapy Dosage; D015996:Survival Rate
chemical_list: D000726:Androgen Antagonists; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone